Deficiency of ZNF341, a transcription factor featuring 12 Cys2His2 zinc fingers that regulates the expression and autoinduction of STAT3 (signal transducer and activator of transcription 3), results in hyper-immunoglobulin E syndrome and defective T helper 17 cell differentiation in humans.
By investigating patients from 10 families who presented with symptoms that resemble monogenic autosomal dominant hyperimmunoglobulin E (IgE) syndrome (AD-HIES) but lacked mutations in signal transducers and activators of transcription 3 (STAT3), two groups-Béziat et al. (1) and Frey-Jakobs et al. (2) -identified a previously unknown player in the pathway that regulates T helper 17 (T H 17) cell differentiation and levels of IgE. The identification of the STAT3 mutations in humans with mono genic AD-HIES (3) has emphasized the importance of this transcription factor in regulating T H 17 cells and the function of these cells in human health and disease. In humans, AD-HIES (also referred to as Job syndrome) is a rare autosomal dominant genetic disorder affecting <1 in 1 million individuals. Major symptoms include immunodeficiency along with elevated IgE, and patients suffer from recurrent bacterial and fungal infections, particularly Candida infections in the lung, along with eczema (3). Patients with AD-HIES also exhibit skeletal abnormalities. Greater than 80% of cases of AD-HIES are a result of mutations in the gene for STAT3, a transcription factor that is a major regulator of T cell responses, particularly T H 17 responses (3). These mutations in STAT3 usually generate dominant-negative mutants that compromise the function of wild-type STAT3. The critical role for STAT3 in negatively regulating T H 2 responses and accompanying elevated IgE may also underlie the T H 2 bias observed in AD-HIES patients.
Cases of syndromes with similarity to AD-HIES have been described in which the precise genetic alterations are unknown but are thought to also interfere with the functioning of the STAT3 pathway. Some of the nonimmune symptoms associated with AD-HIES are observed in individuals that carry mutations in genes that act upstream of STAT3, such as cytokines and cytokine receptors that use STAT3 for signals [for example, leukemia inhibitory factor receptor, interleukin-11 receptor (IL-11R), and the gp130 common subunit of the IL-6 receptor family] (4). Mutations in other genes such as DOCK8 (2) can also lead to symptoms similar to those of AD-HIES, although DOCK8 mutations are associated with an autosomal recessive form of HIES. Notably, DOCK8 regulates STAT3 phosphorylation and T H 17 differentiation (5), further highlighting the importance of STAT3 as a central regulator of HIES.
The importance of STAT3 in regulating T H 17 differentiation underlies the phenotypes and symptoms of the STAT3 mutants. Differentiation of naïve T cells to T H 17 cells depends on signaling via the T cell receptor (TCR) (driven by antigen) and accompanying cytokine signals, usually IL-6 and transforming growth factor- (TGF-), plus or minus IL-1 ( . This phosphorylated tyrosine allows STAT3 to dimerize via its SH2 domain and translocate to the nucleus, where it can regulate genes involved in T H 17 differentiation, including the critical regulator of T H 17 cells, RAR-related orphan receptor-t (RORt) (Fig. 1) (6) . Although this is a major regulatory pathway for STAT3, this signaling can also be potentially regulated by the expression of STAT3. STAT3 is involved in a positive feed-forward loop in cooperation with adenosine 3′,5′-monophosphate (cAMP) response element-binding protein (CREB), which autoregulates its own expression (7). However, despite its importance, few studies have examined how the expression of STAT3 is actually regulated. ZNF382, a zinc fingercontaining transcription factor, has been reported to down-regulate STAT3, possibly via heterochromatin silencing (8) . In addition, Smad3 and its adaptor SPTBN1 are reported to inhibit STAT3 expression (9) .
Enter Béziat et al. (1) and Frey-Jakobs et al. (2) , who analyzed 10 families with reported phenotypes that resemble AD-HIES. The probands from these 10 families are largely from the Middle East (Israel by way of Sudan, Turkey, Iran, and Lebanon), with one AfroCaribbean, and all carried mutations in ZNF341, a putative transcription factor of previously unknown function containing 12 Cys2His2 (C2H2) zinc finger domains. The mutations identified in these studies in ZNF341 are homozygous nonsense mutations that reduce expression partially or completely of ZNF341 and affect the levels of STAT3 in the lymphoid populations. As a result, the reported patients had higher proportions of naïve CD4 + T cells and decreases in central memory CD4 + and CD8 + T cells, as well as mucosal associated invariant T cells, which very closely resembles what is seen in AD-HIES caused by STAT3 dominantnegative mutations.
Although the function of ZNF341 is unknown, it is likely acting as a transcriptional regulator of at least STAT3-and a number of other genes, including STAT1-because it can bind to the STAT3 promoter and activate transcription of a STAT3 reporter plasmid. Furthermore, ectopic expression of ZNF341 in a ZNF341-deficient cell line from one of the carriers was able to rescue expression of STAT1, but surprisingly not STAT3, suggesting a more complex relationship. It is possible that ZNF341 acts along with STAT3 to allow autoregulation of STAT3 because a major phenotype in ZNF341-deficient patients is a lack of T H 17 cells, defective differentiation of IL-17-and IL-22-producing T cells from naïve CD4 + T cells, accompanied by reduced STAT3 phosphorylation secondary to reduced STAT3 expression and lack of induction of STAT3. Furthermore, whereas wild-type ZNF341 is able to enter the nucleus and bind to the STAT3 promoter, mutants that delete the first nuclear localization sequence (R302X) are either unable to enter the nucleus or unable to bind to chromatin or the STAT3 promoter (such as R386X). All of the reported mutations result in deletion of the six N-terminal C2H2 zinc finger domains and disruption of one of the two nuclear localization sequences, suggesting that both of these domains are critical for this function of ZNF341.
Although ZNF341 was also found to interact with the STAT1 promoter and STAT1 expression was enhanced by overexpression of STAT1 in ZNF341-deficient cells, less effect was seen on the expression of STAT1 in the patients with the mutations. However, it is likely that, given its role in regulating the expression of STAT3, ZNF341 may be found to regulate STAT1 under specific circumstances. This relationship between ZNF341 and STAT1 may be interesting in light of the observation that patients with STAT1 gainof-function mutants have similar decreased T H 17 cells and defects in antifungal immune responses, as well as in AD-HIES (10) .
The identification of ZNF341 adds a new twist to the regulation of STAT3 signaling, T H 17 differentiation, and presumably other immunological responses that depend on STAT3 expression or autoinduction. More work needs to be done to fully understand the role of ZNF341 in this pathway because there is no clear induction of STAT3 when ZNF341 is overexpressed, indicating that the regulation of STAT3 expression is more 
